KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Deferred Taxes (2016 - 2025)

Pfizer (PFE) has disclosed Deferred Taxes for 17 consecutive years, with -$433.0 million as the latest value for Q4 2025.

  • Quarterly Deferred Taxes changed N/A to -$433.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.1 billion through Dec 2025, changed N/A year-over-year, with the annual reading at -$2.1 billion for FY2025, 1.47% down from the prior year.
  • Deferred Taxes for Q4 2025 was -$433.0 million at Pfizer, up from -$765.0 million in the prior quarter.
  • The five-year high for Deferred Taxes was $203.0 million in Q2 2021, with the low at -$3.6 billion in Q4 2021.
  • Average Deferred Taxes over 5 years is -$1.1 billion, with a median of -$765.0 million recorded in 2025.
  • The sharpest move saw Deferred Taxes soared 147.56% in 2021, then tumbled 1627.27% in 2022.
  • Over 5 years, Deferred Taxes stood at -$3.6 billion in 2021, then rose by 5.84% to -$3.4 billion in 2022, then surged by 45.34% to -$1.9 billion in 2023, then increased by 8.18% to -$1.7 billion in 2024, then soared by 74.62% to -$433.0 million in 2025.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at -$433.0 million, -$765.0 million, and -$272.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.